Alshurafa Awni, Yassin Mohamed A
Hematology Department, Hamad Medical Corporation, Doha, Qatar.
Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Case Rep Oncol. 2024 Jan 16;17(1):96-100. doi: 10.1159/000535958. eCollection 2024 Jan-Dec.
Chronic myeloid leukemia (CML) is characterized by the presence of the fusion gene, and the advent of tyrosine kinase inhibitors (TKIs) has revolutionized its therapeutic landscape. Asciminib, a STAMP inhibitor, emerges as a promising option for patients unresponsive or intolerant to multiple conventional TKIs. However, the safety and efficacy of asciminib in individuals with chronic kidney disease remain understudied.
In this report, we detail the case of a 62-year-old patient with CML and stage 3 chronic kidney disease, who faced intolerance to traditional TKIs primarily due to fluid retention. The transition to asciminib therapy resulted in a profound molecular response and did not exacerbate renal function, effectively addressing the fluid retention issue.
This case highlights the potential of asciminib as a viable therapeutic alternative for CML patients with chronic kidney disease, particularly those intolerant to standard TKIs. Further research is warranted to establish the broader safety and efficacy profile of asciminib in this patient population.
慢性髓性白血病（CML）的特征是存在融合基因，酪氨酸激酶抑制剂（TKIs）的出现彻底改变了其治疗格局。阿塞西尼布是一种STAMP抑制剂，对于对多种传统TKIs无反应或不耐受的患者而言，它是一个有前景的选择。然而，阿塞西尼布在慢性肾脏病患者中的安全性和有效性仍研究不足。
在本报告中，我们详细介绍了一名62岁的CML合并3期慢性肾脏病患者的病例，该患者主要因液体潴留而对传统TKIs不耐受。改用阿塞西尼布治疗后产生了深度分子反应，且未加重肾功能，有效解决了液体潴留问题。
本病例突出了阿塞西尼布作为慢性肾脏病CML患者，尤其是对标准TKIs不耐受患者的一种可行治疗选择的潜力。有必要进行进一步研究以确定阿塞西尼布在该患者群体中的更广泛安全性和有效性概况。
